Navigation Links
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Date:6/16/2011

02/(ISSN)1097-0142/earlyview">http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142/earlyview.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,  

http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
3. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
4. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
5. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
6. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
7. New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
8. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: ... Patricia Scheller , Viveve,s Chief Executive Officer, and ... at VirtualInvestorConferences.com on July 9, 2015. , , ... , , , , TIME:     , , ... , , , http://tinyurl.com/viveve   , ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... in applications such as animal waste reduction, bioremediation, wastewater treatment, aquaculture and ... settings, announced today that it will be showcasing, ManureMagicâ„¢, its industry-leading product ...
(Date:7/3/2015)... ... July 03, 2015 , ... The ... companies and professional service industries alike-- typically known for its consummate professionalism-- embarks ... a good cause and break from their day jobs. , "Our motto has ...
Breaking Biology Technology:Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2DryLet to Highlight Benefits of Patented ManureMagicâ„¢ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2The Alexander Group Declares Their Independence with a Bit of Levity 2
... , , , , , ... Sensitivity in cDNA Synthesis with the new Transcriptor Reverse, Transcriptase , ... With the new recombinant ,Transcriptor Reverse Transcriptase, you will , , ... Obtain full-length cDNA transcripts , Reverse transcribe difficult templates with high secondary structure ...
... , , , , , , ... Refer to the following table if you observe low transfection efficiency. , , ... Recommendation , , , Nucleic acids of poor quality or ... , Use only high-quality plasmid preparations with no contaminating, ...
... , , , , , ... , , , , ... condition and set a, suitable plating protocol for optimal cell density from the beginning to, ... , , Dividing versus Non-dividing Cells , ...
Cached Biology Technology:Transcriptor Reverse Transcriptase 2Transcriptor Reverse Transcriptase 3Transcriptor Reverse Transcriptase 4Transcriptor Reverse Transcriptase 5Uses and Applications of FuGENE 6 Transfection Reagent 2Uses and Applications of FuGENE 6 Transfection Reagent 3General Considerations for Successful Transfection Experiments 2
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/18/2015)... 2015 This report analyzes the worldwide markets ... Product Segments, which includes Immunoassay Analyzers and Reagents: Enzyme ... Immunoassay Systems, and Nephelometric Immunoassay Systems. The report provides ... , Japan , ... Latin America , and Rest of World. ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... TRANSPORTATION Better, cleaner engines . . . ... in years to come because of a laboratory researchers ... for fuel economy and emissions evaluations. The Vehicle Systems ... to manufacturers of diesel and conventional engines, transmissions, and ...
... A research team led by the Duke-NUS Graduate ... inhibit the function of a key protein linked to ... making it possible to develop drugs that may extend ... in the prestigious international journal Proceedings of the ...
... Conference on Lasers and Electro-Optics (CLEO: 2013) ... (Exhibits open June 11-13) at the San Jose Convention Center, ... the Conference on Lasers and Electro-Optics, is the premier international ... photonic applications and products. CLEO: 2013 builds on the long-established ...
Cached Biology News:June 2013 story tips 2June 2013 story tips 3June 2013 story tips 4Singapore research team identifies new drug target in deadly form of leukemia 2'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 2'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 3'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 4'CLEO: 2013 -- the Premier International Laser and Electro-Optics Event' in San Jose next week 5
Human Cell Line Slides...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Agarose Gel Loading Dye Mixture 6X...
Biology Products: